Stay updated on ACP-196 + Pembrolizumab in Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the ACP-196 + Pembrolizumab in Hematologic Malignancies Clinical Trial page.

Latest updates to the ACP-196 + Pembrolizumab in Hematologic Malignancies Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe recruitment status now indicates the study is not enrolling participants, and new navigation items were added (How to Read a Study Record, Common Questions, How to Join a Study). Additionally, the Intervention/Treatment heading formatting was adjusted and the site revision note updated to Revision: v3.6.0 (replacing v3.5.5).SummaryDifference0.3%

- Check18 days agoChange DetectedRevision updated from v3.5.4 to v3.5.5, indicating a minor administrative update to the page. This change does not affect the study content or displayed data.SummaryDifference0.0%

- Check39 days agoChange DetectedThe study record now shows a new document revision (Revision: v3.5.4) and indicates a Redacted CSR Synopsis, with the prior revision (v3.5.3) removed.SummaryDifference0.2%

- Check61 days agoChange DetectedThis updates the displayed interface/version identifier on the page (revision v3.5.0 → v3.5.3).SummaryDifference0.0%

- Check89 days agoChange DetectedAdded Waldenström macroglobulinemia, Richter syndrome, and B-cell chronic lymphocytic leukemia to the conditions section, and updated site revision from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check111 days agoChange DetectedThe page now displays revision number v3.4.3, replacing the previous v3.4.2.SummaryDifference0.0%

Stay in the know with updates to ACP-196 + Pembrolizumab in Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACP-196 + Pembrolizumab in Hematologic Malignancies Clinical Trial page.